Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.71 CAD 11.76%
Market Cap: 141.3m CAD

Cardiol Therapeutics Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Net Issuance of Common Stock
CA$21.4m
CAGR 3-Years
-37%
CAGR 5-Years
120%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Net Issuance of Common Stock
CA$394m
CAGR 3-Years
263%
CAGR 5-Years
56%
CAGR 10-Years
45%
Sundial Growers Inc
NASDAQ:SNDL
Net Issuance of Common Stock
-CA$28.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Net Issuance of Common Stock
-$3.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Net Issuance of Common Stock
-CA$10.6m
CAGR 3-Years
43%
CAGR 5-Years
34%
CAGR 10-Years
N/A

Cardiol Therapeutics Inc
Glance View

Market Cap
141.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
Not Available

See Also

What is Cardiol Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
21.4m CAD

Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Net Issuance of Common Stock amounts to 21.4m CAD.

What is Cardiol Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
120%

Over the last year, the Net Issuance of Common Stock growth was 23 673%. The average annual Net Issuance of Common Stock growth rates for Cardiol Therapeutics Inc have been -37% over the past three years , 120% over the past five years .

Back to Top